MD3999643T2 - Metode de tratament sau prevenire a atrofiei musculare spinale - Google Patents

Metode de tratament sau prevenire a atrofiei musculare spinale Download PDF

Info

Publication number
MD3999643T2
MD3999643T2 MDE20220574T MDE20220574T MD3999643T2 MD 3999643 T2 MD3999643 T2 MD 3999643T2 MD E20220574 T MDE20220574 T MD E20220574T MD E20220574 T MDE20220574 T MD E20220574T MD 3999643 T2 MD3999643 T2 MD 3999643T2
Authority
MD
Moldova
Prior art keywords
antisense compound
salt
dose
administered
doses
Prior art date
Application number
MDE20220574T
Other languages
English (en)
Romanian (ro)
Inventor
Kenneth Swope Loveday
Fengju Judy Bai
Lilly East
Wildon R Farwell
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71995097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MD3999643(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MD3999643T2 publication Critical patent/MD3999643T2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
MDE20220574T 2019-07-19 2020-07-16 Metode de tratament sau prevenire a atrofiei musculare spinale MD3999643T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962876360P 2019-07-19 2019-07-19
PCT/US2020/042312 WO2021016032A1 (en) 2019-07-19 2020-07-16 Methods of treating or preventing spinal muscular atrophy

Publications (1)

Publication Number Publication Date
MD3999643T2 true MD3999643T2 (ro) 2024-02-29

Family

ID=71995097

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20220574T MD3999643T2 (ro) 2019-07-19 2020-07-16 Metode de tratament sau prevenire a atrofiei musculare spinale

Country Status (33)

Country Link
US (3) US20220325282A1 (cg-RX-API-DMAC7.html)
EP (2) EP4335503A3 (cg-RX-API-DMAC7.html)
JP (3) JP7279253B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220042113A (cg-RX-API-DMAC7.html)
CN (1) CN114302727A (cg-RX-API-DMAC7.html)
AR (1) AR119430A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020316997A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000870A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149906A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003602A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001354A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220071A (cg-RX-API-DMAC7.html)
DK (1) DK3999643T5 (cg-RX-API-DMAC7.html)
ES (1) ES2966791T3 (cg-RX-API-DMAC7.html)
FI (1) FI3999643T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231515T1 (cg-RX-API-DMAC7.html)
HU (1) HUE064071T2 (cg-RX-API-DMAC7.html)
IL (1) IL289745A (cg-RX-API-DMAC7.html)
JO (2) JOP20220007A1 (cg-RX-API-DMAC7.html)
LT (1) LT3999643T (cg-RX-API-DMAC7.html)
MA (1) MA62935B1 (cg-RX-API-DMAC7.html)
MD (1) MD3999643T2 (cg-RX-API-DMAC7.html)
MX (1) MX2022000441A (cg-RX-API-DMAC7.html)
PE (1) PE20220941A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550114A1 (cg-RX-API-DMAC7.html)
PL (1) PL3999643T3 (cg-RX-API-DMAC7.html)
PT (1) PT3999643T (cg-RX-API-DMAC7.html)
RS (1) RS64879B1 (cg-RX-API-DMAC7.html)
SI (1) SI3999643T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300442T1 (cg-RX-API-DMAC7.html)
TW (2) TW202438086A (cg-RX-API-DMAC7.html)
UY (1) UY38790A (cg-RX-API-DMAC7.html)
WO (1) WO2021016032A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3797780B1 (en) 2014-04-17 2022-09-14 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing in a subject
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
PT3999643T (pt) 2019-07-19 2023-12-11 Biogen Ma Inc Métodos de tratamento da atrofia muscular espinhal
WO2024138018A1 (en) * 2022-12-23 2024-06-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Treatment of gemin5-mediated disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3470072A1 (en) * 2005-06-23 2019-04-17 Biogen MA Inc. Compositions and methods for modulation of smn2 splicing
WO2008157753A1 (en) * 2007-06-21 2008-12-24 Sma Foundation Methods of treatment for spinal muscular atrophy
ES2699827T3 (es) 2009-06-17 2019-02-13 Biogen Ma Inc Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
WO2011032109A1 (en) 2009-09-11 2011-03-17 Sma Foundation Biomarkers for spinal muscular atrophy
EP2714037B1 (en) * 2011-05-25 2016-07-13 Université Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
WO2014110291A1 (en) 2013-01-09 2014-07-17 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of smn2 splicing in a subject
US10436802B2 (en) 2014-09-12 2019-10-08 Biogen Ma Inc. Methods for treating spinal muscular atrophy
EP3484524B1 (en) * 2016-07-15 2022-11-09 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of smn2
TW201927241A (zh) 2017-12-21 2019-07-16 瑞士商赫孚孟拉羅股份公司 用於肌肉失能之數位生物標記
CN119679944A (zh) 2018-01-25 2025-03-25 渤健马萨诸塞州股份有限公司 治疗脊髓性肌萎缩症的方法
IT201800004359A1 (it) 2018-04-10 2019-10-10 IDENTIFICAZIONE DI miRNA MUSCOLARI COME BIOMARCATORI E TRATTAMENTO CO-ADIUVANTE PER L’ATROFIA MUSCOLARE SPINALE
US20210308281A1 (en) * 2018-08-15 2021-10-07 Biogen Ma Inc. Combination therapy for spinal muscular atrophy
PT3999643T (pt) 2019-07-19 2023-12-11 Biogen Ma Inc Métodos de tratamento da atrofia muscular espinhal

Also Published As

Publication number Publication date
US20250230440A1 (en) 2025-07-17
PE20220941A1 (es) 2022-05-31
TWI841762B (zh) 2024-05-11
ES2966791T3 (es) 2024-04-24
US20220325282A1 (en) 2022-10-13
EP4335503A3 (en) 2024-06-05
JOP20220007A1 (ar) 2023-01-30
HRP20231515T1 (hr) 2024-03-01
TW202116331A (zh) 2021-05-01
US20240318182A1 (en) 2024-09-26
TW202438086A (zh) 2024-10-01
FI3999643T3 (fi) 2023-11-30
BR112022000870A2 (pt) 2022-03-22
JOP20250103A1 (ar) 2025-05-05
KR20220042113A (ko) 2022-04-04
EP3999643B1 (en) 2023-11-22
DK3999643T5 (da) 2024-08-05
JP2025096486A (ja) 2025-06-26
IL289745A (en) 2022-03-01
LT3999643T (lt) 2023-12-11
CN114302727A (zh) 2022-04-08
SMT202300442T1 (it) 2024-01-10
AU2020316997A1 (en) 2022-03-10
CL2021003602A1 (es) 2022-10-14
AR119430A1 (es) 2021-12-15
DK3999643T3 (da) 2023-12-04
PT3999643T (pt) 2023-12-11
JP7279253B2 (ja) 2023-05-22
EP4335503A2 (en) 2024-03-13
HUE064071T2 (hu) 2024-02-28
JP2022540993A (ja) 2022-09-21
MA62935B1 (fr) 2023-11-30
CA3149906A1 (en) 2021-01-28
RS64879B1 (sr) 2023-12-29
UY38790A (es) 2021-01-29
PH12022550114A1 (en) 2023-04-17
PL3999643T3 (pl) 2024-02-19
SI3999643T1 (sl) 2024-01-31
CO2022001354A2 (es) 2022-03-18
WO2021016032A1 (en) 2021-01-28
JP2023100911A (ja) 2023-07-19
CR20220071A (es) 2022-04-22
MX2022000441A (es) 2022-03-25
JP7665678B2 (ja) 2025-04-21
EP3999643A1 (en) 2022-05-25

Similar Documents

Publication Publication Date Title
MD3999643T2 (ro) Metode de tratament sau prevenire a atrofiei musculare spinale
Ai et al. MicroRNA-195 protects against dementia induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats
Nance Spinal muscular atrophy
US9533002B2 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β
BR112021010660A2 (pt) Proteína de neurofilamento para guiar intervenção terapêutica sobre esclerose lateral amiotrófica
Andreone et al. Durable suppression of seizures in a preclinical model of KCNT1 genetic epilepsy with divalent small interfering RNA
HK40108697A (en) Methods of treating or preventing spinal muscular atrophy
EA047168B1 (ru) Способы лечения или предотвращения спинальной мышечной атрофии
US20260022377A1 (en) Polynucleotide compositions and methods for treatment of neurodegenerative diseases
Zhang et al. Extracellular histone H3 induces macrophage inflammation in acute liver failure via HDAC2 activation and PKM2 subcellular relocalization
EA052680B1 (ru) Способы лечения или предотвращения спинальной мышечной атрофии
AU2023373192A1 (en) Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases
Bailey et al. AAV-mediated gene therapy for SLC13A5 Citrate Transporter Disorder rescues epileptic and metabolic phenotypes
Rodriguez et al. A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction
CN120037378A (zh) microRNA-21-3p作为靶点在制备治疗脑海绵状血管畸形的药物中的应用
CN121648301A (zh) Gpr84抑制剂在制备治疗脓毒症肝损伤的药物中的用途
HK40107707A (zh) 用於治疗阿尔茨海默病的组合物和方法
EP3927378A1 (en) Method for reduction drug-induced nephrotoxicity